Zhitong Financial APP learned that Konoya-B (02162) announced that the company is developing a new drug CMG901 ("Claudin 18.2 antibody coupling drug") for the treatment of ╱ refractory gastric cancer and gastroesophageal junction adenocarcinoma has recently been granted fast track qualification (Fast Track Designation, "FTD") by the US Food and Drug Administration ("FDA"). As of 13:26, it was up 5.89% to quote HK $23.35, with a turnover of 2.3606 million.

It is reported that CMG901 is an antibody coupling drug targeting Claudin18.2, which contains Claudin18.2 specific antibodies, cleavable connectors and toxic payload-methylolastatin E (MMAE). It is the first Claudin18.2 antibody coupling drug approved in clinical trials in China and the United States. Claudin 18.2 is specifically highly expressed in gastric cancer, pancreatic cancer and other solid tumors, making it an ideal target for cancer therapy.